Latest Compass Pathways News & Updates

See the latest news and media coverage for Compass. We track all announcements, press releases, and industry mentions in real time, all in one place.

Compass Pathways (Compass)

Mental health biotechnology company

compasspathways.com

Headquarters: London, United Kingdom
Founded year: 2016
Company type: Public company
Number of employees: 50–300
Industry: Pharmaceuticals

Last updated Today

Latest news about Compass Pathways (Compass)

In short: Compass reported positive 52-week Phase 3 results for its COMP360 psilocybin treatment and progressed toward a Q4 FDA submission.

Company announcements

Yesterday Compass

Compass awards grants for COMP360 provider training

Five organizations selected to develop training for healthcare providers preparing for the potential commercial launch of the psychedelic treatment.

September 9 Compass

Compass reports positive 52-week COMP360 trial data

Results show sustained durability and strong response rates for treatment-resistant depression, supporting the NDA submission in Q4 with a targeted launch in H1 2027.

August 27 Compass

Compass Pathways welcomes Ilya Sokol as VP of Finance

Sokol joins from PTC Therapeutics, bringing expertise in scaling finance functions and navigating organizational growth milestones for the company's next phase.

May 28 Compass

Compass Elects Kathleen Tregoning to Its Board of Directors

Tregoning brings extensive biopharma strategy and public policy experience, joining as the company advances its COMP360 psilocybin treatment through regulatory review.

Media coverage

September 9 AFP

Compass Pathways' New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today the topline 52-week...

September 9 Yahoo Finance

Compass Pathways reports 52-week Phase 3 COMP005 results for COMP360

Compass Pathways plc (NASDAQ:CMPS) reported 52-week topline results from Part C of its Phase 3...

September 9 Psychiatric Times

New 6-Month Data From Second Phase 3 Trial Confirms Rapid Effect of COMP360 for TRD | Psychiatric Times

Phase 3 data show COMP360 psilocybin delivers rapid, lasting relief in treatment-resistant...

September 8 Yahoo Finance

CMPS Stock Rallies On Launch-Prep Push Ahead Of FDA Psychedelics Hearing

Compass has said a rolling FDA application is already underway for its COMP360, with the package due...

Never miss news about Compass

Track Compass and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Compass competitors & trending companies

Browse news for competitors to Compass and other trending companies.